serplulimab
fosun pharmaceuticals
['lcsm,(-blcsm)', 'serplulimab', 'sclc']
#asco22 abs #8505 phase 3 study in 1st line es-sclc, #serplulimab (pd1i) + chemo vs chemo by chen et al. mos: 15.4 vs 10.9 mths mpfs: 5.8 vs 4,3 m pd-1 inhibitor in #sclc #lcsm 
Fellow @MayoHemeOnc | @UConnIM| @UTexasSPH| @MDAndersonNews|@COVID19nCCC| #SoMeEditor @JCOCCI_ASCO| Co-Host @HemOncFellows https://t.co/dsiuV460lQ, Views my own